Lutetium-177MeSH Supplementary Concept

https://www.has-sante.fr/jcms/p_3518264/fr/lunca-chlorure-de-lutetium-177lu-precurseur-radiopharmaceutique
2024
France
evaluation of the transparency committee
chloride salt, nos
halogenation
Precursor Radiopharmaceutical Dosage Form
Chloride Measurement
Lutetium-177
Chloride Ion
radiopharmaceuticals
Chloride
lutetium
chlorides
Chloride
urine chloride
chlorination

---
https://www.ema.europa.eu/en/medicines/human/EPAR/pluvicto
2023
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
radiopharmaceuticals
Lutetium Lu 177 Vipivotide Tetraxetan
Lutetium Lu 177 Vipivotide Tetraxetan
lutetium (177Lu) vipivotide tetraxetan
radiopharmaceuticals
radiopharmaceuticals
Lutetium-177
prostatic neoplasms, Castration-Resistant
neoplasm metastasis
PSMA-Positive Tumor
antineoplastic combined chemotherapy protocols
injections, intravenous
infusions, intravenous
FOLH1 protein, human
product surveillance, postmarketing
pregnancy
breast feeding

---
https://www.has-sante.fr/jcms/p_3434491/fr/endolucin-beta-chlorure-de-lutetium-177-lu-no-carrier-added-n-c-a-precurseur-radiopharmaceutique
2023
false
false
false
France
Radiopharmaceutical precursor (qualifier value)
Radioisotopic Labeling
insurance, health, reimbursement
evaluation of the transparency committee
Lutetium-177
lutetium

---
https://www.ema.europa.eu/en/medicines/human/EPAR/illuzyce
2022
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Lutetium-177
Radioisotopic Labeling
drug approval
europe
neuroendocrine tumors
prostatic neoplasms
radiopharmaceuticals
other therapeutic radiopharmaceuticals
Precursor Radiopharmaceutical Solution Dosage Form

---